

Rafael Molina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4065817/publications.pdf>

Version: 2024-02-01

33
papers

1,840
citations

279798

23
h-index

414414

32
g-index

34
all docs

34
docs citations

34
times ranked

2465
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour markers with clinically controlled cut-offs for suspected cancer. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13523.	3.4	3
2	Very high levels of PSA in patients with cardiogenic shock: Report of four clinical cases. <i>Clinical Biochemistry</i> , 2020, 76, 42-44.	1.9	2
3	A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test. <i>Tumor Biology</i> , 2020, 42, 101042832095860.	1.8	3
4	Comparative Assessment of Two Strategies for Interpreting Tumor Markers in Ascitic Effusions. <i>In Vivo</i> , 2020, 34, 715-722.	1.3	1
5	Diagnostic Accuracy of CYFRA21-1 in the Differential Diagnosis of Pleural Effusions. <i>Anticancer Research</i> , 2019, 39, 5071-5076.	1.1	2
6	Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer. <i>Tumor Biology</i> , 2018, 40, 101042831877220.	1.8	12
7	Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1945-1953.	2.3	15
8	Evaluation of two strategies for the interpretation of tumour markers in pleural effusions. <i>Respiratory Research</i> , 2017, 18, 103.	3.6	16
9	Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1333-1340.	2.5	35
10	Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. <i>Clinica Chimica Acta</i> , 2015, 438, 388-395.	1.1	30
11	Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers. <i>Clinical Chemistry</i> , 2015, 61, 809-820.	3.2	120
12	The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10 ¹ / ₄ g/L. <i>Clinica Chimica Acta</i> , 2014, 436, 303-307.	1.1	28
13	Risk Stratification for Advanced Colorectal Neoplasia According to Fecal Hemoglobin Concentration in a Colorectal Cancer Screening Program. <i>Gastroenterology</i> , 2014, 147, 628-636.e1.	1.3	94
14	Circulating levels of HER-2/neu oncoprotein in breast cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 5-21.	2.3	27
15	Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. <i>Tumor Biology</i> , 2012, 33, 463-474.	1.8	52
16	Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. <i>Tumor Biology</i> , 2011, 32, 13-22.	1.8	28
17	HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. <i>Tumor Biology</i> , 2011, 32, 1087-1095.	1.8	133
18	Diagnostic relevance of circulating biomarkers in patients with lung cancer. <i>Cancer Biomarkers</i> , 2010, 6, 163-178.	1.7	75

#	ARTICLE	IF	CITATIONS
19	Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. <i>Tumor Biology</i> , 2010, 31, 171-180.	1.8	61
20	Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer. <i>Clinical Chemistry</i> , 2010, 56, 1148-1157.	3.2	70
21	Usefulness of Serum Tumor Markers, Including Progastrin-Releasing Peptide, in Patients with Lung Cancer: Correlation with Histology. <i>Tumor Biology</i> , 2009, 30, 121-129.	1.8	94
22	Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access [®] BR Monitor assay on the UniCel [®] DxI 800 Immunoassay System. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 612-22.	2.3	10
23	Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE. <i>Tumor Biology</i> , 2008, 29, 371-380.	1.8	107
24	Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations. <i>Tumor Biology</i> , 2005, 26, 281-293.	1.8	287
25	CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. <i>Anticancer Research</i> , 2005, 25, 1765-71.	1.1	26
26	Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. <i>Anticancer Research</i> , 2005, 25, 1773-8.	1.1	66
27	Pro-Gastrin-Releasing Peptide in Patients with Benign and Malignant Diseases. <i>Tumor Biology</i> , 2004, 25, 56-61.	1.8	44
28	ProGRP: a new biomarker for small cell lung cancer. <i>Clinical Biochemistry</i> , 2004, 37, 505-511.	1.9	118
29	Prospective Evaluation of Squamous Cell Carcinoma and Carcinoembryonic Antigen as Prognostic Factors in Patients with Cervical Cancer. <i>Tumor Biology</i> , 2003, 24, 156-164.	1.8	36
30	S-100 Protein Serum Levels in Patients with Benign and Malignant Diseases: False-Positive Results Related to Liver and Renal Function. <i>Tumor Biology</i> , 2002, 23, 39-44.	1.8	56
31	Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia. , 2000, 42, 181-185.		31
32	Analysis of type T1 and T2 cytokines in patients with prostate cancer. <i>Prostate</i> , 2000, 44, 271-274.	2.3	54
33	c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. <i>Breast Cancer Research and Treatment</i> , 1998, 51, 109-119.	2.5	104